RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIODS ENDED SEPTEMBER 30, 2026
RETRACTABLE TECHNOLOGIES INC (RVP) filed an SEC Form 8-K — Other Events. Exhibit 99 RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIODS ENDED SEPTEMBER 30, 2026 LITTLE ELM, TEXAS, November 16, 2026 — Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $14.1 million for the third quarter of 2026 and an operating loss of $4
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations for RVP’s revenue quality, gross margin drivers (EasyPoint versus syringe mix), and tariff-related cost trajectory based on the quarter and nine-month figures.
Market read
Fresh quarterly operating loss and detailed drivers (tariffs, domestic production share, EasyPoint mix, international order uncertainty) can influence positioning ahead of the 10-Q and subsequent analyst modeling.
What to watch
International order timing uncertainty could reverse the positive unit-sales momentum; also, the nine-month realized gain on equity sales may mask underlying operating weakness.
Background
The filing is an SEC 8-K furnishing results for the periods ended Sept. 30, 2026, with additional detail to be found in the company’s 10-Q filed the same day.
Ticker impact
Retractable Technologies reports Q3 2026 net sales of $14.1M and an operating loss of $4.1M, plus tariff and cost-mix drivers.
Likely modest pressure or choppy trading as investors weigh continued operating losses against tariff-cost mitigation and unit growth.
The 8-K provides fresh quarterly operating results and specific drivers (tariffs, domestic production share, EasyPoint mix) that can change near-term expectations, but it does not include guidance or a clear inflection to profitability.
Market effects
Highlights ongoing margin pressure from product mix and tariffs for medical device manufacturers, with mitigation via domestic production.
Limited direct regional read-through; domestic production and Chinese sourcing are the key operational levers.
Tariff exposure and international order timing remain relevant for cross-border medical supply chains.
Counterpoint
The operating loss widened mainly due to gross margin mix, while unit sales rose sharply and tariff expenses declined versus prior periods, suggesting the cost structure could improve faster than earnings imply.
Key entities
- companyRetractable Technologies, Inc.
NYSE American-listed medical device maker reporting Q3 and nine-month 2026 results and discussing tariff mitigation and product mix.


